glp 1 trends Glucagon-like peptide-1 receptor: mechanisms and advances in therapy Trends in glucagon-like peptide 1

Although the carnitine level can drop so far that the fatty acid oxidation is inhibited, no cases of an illness due to a lack of carnitine have yet been described

In 2005, the first drug, exenatide, derived from Gila monster saliva, hit the market

From weight loss to neurological deficits: a case of Wernickes encephalopathy stemming from prescription weight loss medication

Despite the lack of research on tirzepatide, especially in HF patients, its cardiovascular effects indicate potential benefits for this population

Gurbuz N, Aksu T, Van Noorden C

Insulin sensitivity changes Growth hormone has complex effects on glucose metabolism